Sildenafil Tablet, Film Coated
Product Images NDC 55154-4307

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 55154-4307). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 01)

A line chart depicting the estimated cumulative mortality rate (%) over time (years) for three dosage groups: high dose, medium dose, and low dose. The y-axis shows mortality rates from 0 to 25%, and the x-axis spans 0 to 5 years. The chart includes at-risk population numbers at specific years for each dose group, with high dose showing the highest mortality curve, medium dose intermediate, and low dose the lowest.*

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 02)

Chemical structure diagram of Sildenafil, showing its molecular framework with various rings and functional groups, consistent with the pharmaceutical compound Sildenafil.*

FDA Label Image

7 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 03)

A scatter plot chart illustrating fold change and 90% confidence intervals for pharmacokinetic parameters (AUC and Cmax) of various interacting drugs relative to sildenafil alone. The horizontal axis shows change relative to sildenafil from 0.2 to 13 on a log scale. A vertical solid line at x=1 marks no change. Recommendations for dose adjustments or coadministration are noted for each drug.*

FDA Label Image

8 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 04)

A chart depicting fold changes and 90% confidence intervals for various pharmacokinetic parameters (AUC, Cmax, INR) when sildenafil is coadministered with different interacting drugs. It shows changes relative to the interacting drug alone for drugs including Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin, Ethinylestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide, along with corresponding dose adjustment recommendations.*

FDA Label Image

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)

A line chart depicting change from baseline in meters over three study weeks (Week 4, Week 8, and Week 12) for four groups: Placebo, Sildenafil 20mg TID, Sildenafil 40mg TID, and Sildenafil 80mg TID. Data points include error bars representing variability across the measurements.*

FDA Label Image

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)

A forest plot chart depicting placebo-corrected changes in 6-minute walk distance in meters for patients treated with Sildenafil 20 mg TID. The chart compares subgroups based on baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary arterial pressure, and pulmonary vascular resistance index, with point estimates and confidence intervals shown for each subgroup.*

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 07)

Kaplan-Meier plot depicting the percentage of subjects without a clinically worsening event over time (in days) from randomization in Study 2. The graph compares placebo and sildenafil groups, showing their respective survival curves up to 112 days.*

FDA Label Image

Figure 12 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 08)

A line graph showing the mean change from baseline in six-minute walk distance (meters) over a 12-week study period for Sildenafil at doses of 1 mg TID, 5 mg TID, and 20 mg TID. The x-axis represents weeks 4, 8, and 12, while the y-axis shows change from baseline in meters with error bars indicating standard error for each dose group.*

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 09)

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 10)

FDA Label Image

Bag Label (C5ac2265 393a 4fbe B974 1dd0b9243ec8 00)

This drug facts label for Sildenafil Tablets, USP contains key product details including the 20 mg strength and a 10-tablet count. It provides usage and storage instructions, emphasizing the prescription status, pharmacist dispensing requirements, and storage temperature range. The label also lists manufacturers and distributors.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.